Check 35,000+ stocks against 26 valuation models and 37 quality factors

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ¥26.64, price ¥19.39, upside +37.4%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · CN · ISIN CNE000001733

GB Broad data Sep 24, 2026

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

600332 · SHG

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value ¥26.64 · Undervalued (+37%)

!Quality 51/100

!Expensive Growth (revenue 5y +4.7 %/yr)

!Thin margins · 3.8% net margin (TTM)

!Low debt · negative free cash flow

·4.38% dividend yield

!Mixed vs. peers (8/14)

!Narrow moat 36/100

!Weak on future: 18 out of 100

26 models, one by oneBear ¥22.32 to bull ¥41.36 Growth analysisrevenue history, year by year Quality 51/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥19.39 – ¥35.92 · fair‑value band ¥22.32 – ¥41.36 · the ¥19.39 price screens below the ¥26.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Guangzhou Baiyunshan Pharmaceutical Holdings Co in your weekly email

Every Wednesday you see whether Guangzhou Baiyunshan Pharmaceutical Holdings Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices. The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup. In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services. Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Stock analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) currently trades at ¥19.39, while our model-based Fair Value estimate is ¥26.64, implying the stock looks roughly 27.2% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of ¥57.24 per share, and 14 of the 17 models we run sit above the ¥19.39 price.

Bear case: the Dividend Discount group reads lowest at ¥13.99, and 3 of the 17 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥22.32 (bear) to ¥41.36 (bull), the price of ¥19.39 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd reported revenue of 77.4B CNY in FY2025 versus 69.0B CNY in FY2021, a compound +2.9%/yr. Reported net income was 3.0B CNY in FY2025, compounding −5.4%/yr from FY2021.

Key figures

Market cap 34.8B CNY (≈ $5.2B) · P/E ratio 11.8 · P/S ratio 0.46 · EPS (TTM) ¥1.81 · Dividend yield 4.4% · Net margin 3.9% · Return on equity 7.4% · Return on assets (EBIT) 5.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 37%, 600332 screens cheaper than that median.

Fair Value models

Bear ¥22.32 Fair Value ¥26.64 Bull ¥41.36

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.7049 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Residual Income ¥22.05 ¥23.48 ¥25.81 76

Owner Earnings ¥35.36 ¥57.24 ¥94.63 75

EPV ¥24.36 ¥26.88 ¥29.06 74

All 17 models by family

DCF Models

Owner Earnings ¥35.36 ¥57.24 ¥94.63 75

Earnings-Based

Graham-Dodd ¥14.43 ¥70.50 ¥97.15 64

Lynch FV ¥18.92 ¥27.03 ¥35.14 61

PEG = 1.0 ¥18.92 ¥27.03 ¥35.14 57

EPV ¥24.36 ¥26.88 ¥29.06 74

Dividend Discount

Gordon GGM ¥8.13 ¥16.19 ¥24.52 67

DDM Multi-Stage ¥8.13 ¥13.99 ¥17.09 67

Multiples

P/E Multiple ¥35.01 ¥46.68 ¥58.35 63

P/S Multiple ¥27.05 ¥36.07 ¥45.09 58

P/B Multiple ¥27.05 ¥36.07 ¥45.09 55

EV/EBIT ¥36.50 ¥45.88 ¥55.25 66

EV/EBITDA ¥38.67 ¥48.78 ¥58.88 67

EV/Revenue ¥28.45 ¥37.05 ¥45.66 54

Asset-Based

NCAV (Graham) ¥13.44 ¥18.01 ¥26.88 54

Economic Profit

Residual Income ¥22.05 ¥23.48 ¥25.81 76

ROIC Compounder ¥24.36 ¥26.89 ¥32.10 72

Growth Earnings

Growth-Adj P/E ¥30.03 ¥42.89 ¥55.76 67

Open the full fair value analysis →

Notify me when 600332 reaches fair value

Put 600332 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 48 · Market factors (momentum, volatility) 40

Profitability 38

Margins and returns on capital today

Quality Growth 42

Are margins and returns improving?

Cashflow 7

Earnings quality: real cash, not paper profit

Fin. Strength 62

Balance sheet, leverage, solvency risk

Investment 84

Disciplined investing over empire-building

Low Volatility 97

Calm price path (market factor)

Momentum 24

Price trend over the last 3–12 months (market factor)

52W Momentum 2

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+3.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.7%

Start year 2020 (pandemic). Over 10 years: +15.0% a year

Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+12.2%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+3.1%

Earnings growth per share plus dividend.

Earnings per share, growth per year−1.3%

Dividend (yield on the price)4.4%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1% vs 6%, slowing

Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 4%

Start year 2020 (pandemic)

Watch 600332, get fair value alerts →

Compare Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 8/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 51 · Below median

Fair Value upside +37% · Above median

Profitability

Return on equity (TTM) 7% · Above median

Return on assets 2% · Below median

Net margin (TTM) 4% · Above median

Operating margin (TTM) 9% · Top 25%

Growth and dividend

Revenue growth 4% · Above median

Dividend yield (TTM) 4.4% · Above median

Balance sheet

Debt / equity 0.08× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 11.8× · Cheaper than median

P/B 0.92× · Pricier than median

P/S (TTM) 0.44× · Pricier than median

EV/EBITDA 6.0× · Cheaper than median

PEG 2.93× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)83 · sector 44

FUTURE (revenue growth)18 · sector 15

PAST (return on equity)30 · sector 27

HEALTH (low debt)96 · sector 96

DIVIDEND (yield)88 · sector 59

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation MCK	$880.50	$819.31	−7%
Cencora, Inc COR	$312.28	$211.07	−32%
Cardinal Health, Inc CAH	$221.27	$141.77	−36%
Henry Schein, Inc HSIC	$87.43	$76.86	−12%
Shanghai Pharmaceuticals Holding 601607	¥16.06	¥42.67	+166%
Sinopharm Group 1099	HK$15.06	HK$58.89	+291%
Galenica AG GALE	CHF 83.45	CHF 61.79	−26%
Jointown Pharmaceutical Group 600998	¥4.89	¥9.84	+101%
China National Medicines Corporation 600511	¥26.11	¥58.47	+124%
Asker Healthcare Group ASKER	kr 60.90	kr 28.26	−54%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd · Fair Value
¥26.64 +27%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/600332" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd · Fair Value</span><br><b style="font-size:20px">¥26.64</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+27%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600332

Frequently asked questions

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ¥26.64 versus a price of ¥19.39, about +37% upside (undervalued).

What is the fair value of 600332?

Our model-based fair value for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is ¥26.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥19.39.

What is the quality score of 600332?

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Our model-based price target is the fair value of ¥26.64 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ¥22.32, optimistic scenario ¥41.36. It is a calculation from audited fundamentals, not an analyst target.

What is the Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd stock forecast for 2026?

Our models put fair value at ¥26.64, about +37% upside versus a price of ¥19.39 (undervalued). Cautious scenario ¥22.32, optimistic scenario ¥41.36. The calculation is refreshed regularly with new filings.

What is the revenue of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd reported trailing-twelve-month revenue of about 78.5B CNY (latest available figure, as of Sep 24, 2026).

Does Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd pay a dividend?

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd currently shows a dividend yield of about 4.38% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd it is ¥26.64 per share (as of Sep 24, 2026), against a price of ¥19.39. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 600332 trades below its calculated fair value: price ¥19.39, fair value ¥26.64, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 600332?

No. The price is what the market pays today (¥19.39); the fair value is what the company's own numbers justify (¥26.64). For Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd the two are ¥7.25 per share apart. That gap is exactly why we show both numbers side by side.

How much is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd worth?

The market values Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd at about 34.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥19.39; our models calculate a fair value of ¥26.64 per share.

What do the bullish and bearish scenarios say about 600332?

Our models span a range for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd: cautious scenario ¥22.32, base ¥26.64, optimistic ¥41.36 per share (as of Sep 24, 2026, price ¥19.39). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 600332?

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd trades at a price-to-earnings ratio of 11.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥26.64 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 13.3 (reported for FY2025: 10.6). Other multiples: PEG 2.9, P/B 0.9, P/S 0.4, EV/EBITDA 6.0.

What is the PEG ratio of 600332?

The PEG ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 2.93 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Balance-sheet figures for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (as of Sep 24, 2026): return on equity 7.4%, debt of 0.08 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.

How far is 600332 from its 52-week high?

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd trades at ¥19.39, about 29% below its 52-week high of ¥27.37 and at the low of ¥19.39 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥26.64 is for.

Which stocks are comparable to Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?

From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd stock attractive at the current price?

The data as of Sep 24, 2026: price ¥19.39, calculated fair value ¥26.64 (+37%), Quality Score 51/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 600332 calculated?

We run Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥26.64, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.0 % above its aggregate fair value. Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd currently trades 37 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The closing price on Sep 24, 2026 was ¥19.39. Our model-based fair value is ¥26.64, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd right now?

The price is below even our cautious bear case (¥22.32). The market is more pessimistic than our downside scenario. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (¥22.32 to ¥41.36) leaves room in how you read the outcome.

Where does the earnings growth of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) come from?

Earnings per share at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd grew +8.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.8 %, EBIT margin −3.7 %, tax rate +0.2 %, residual (interest, one-offs) −1.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

How large is the market capitalisation of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The market capitalisation of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 34.8B CNY (≈ $5.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The price-to-sales ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 0.46 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Earnings per share at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd are ¥1.81 (price ÷ EPS = P/E 11.8). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The dividend yield of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 4.4% (payout 47.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The net margin of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 3.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The return on equity (ROE) of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

On an EBIT basis the return on assets of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

The operating margin of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Revenue at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is growing +3.6% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)?

Earnings per share at Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd are growing −2.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) generate?

The free cash flow of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is −980M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) carry?

The net debt of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is 5.7B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd in the live analysis

One click puts Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.